| Ms Lauren Elizabeth Kleess, MD | |
|
1045 N 30th St, Billings, MT 59101-0738 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | Ms Lauren Elizabeth Kleess |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 11 Years |
| Location | 1045 N 30th St, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346689544 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Sheridan Memorial Hospital | Sheridan, WY | Hospital |
| Roundup Memorial Healthcare | Roundup, MT | Hospital |
| Central Montana Medical Center | Lewistown, MT | Hospital |
| Cody Regional Health | Cody, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Conway Hospital Inc | 7113839606 | 98 |
| Billings Clinic | 6002993516 | 659 |
News Archive
Scientists at the University of Bonn and the Hebrew University of Jerusalem (Israel) have decoded a central signal cascade associated with epileptic seizures. If the researchers blocked a central switch in epileptic mice, the frequency and severity of the seizures decreased. Using a novel technology, it was possible to observe the processes prior to the occurrence of epileptic seizures in living animals.
Screening African Americans for microalbuminuria at either 5- or 10-year intervals would be highly cost-effective using a modified version of the CKD Health Policy Model, US researchers report.
Despite maturity in some segments, the European patient monitoring market still offers pockets of high growth potential. Unique strategies and technologically innovative products will sustain further expansion, even as the enthusiasm of patients and doctors for more sophisticated offerings will counteract challenges faced by the market.
The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.
Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.
› Verified 9 days ago
| Entity Name | Conway Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134172000 PECOS PAC ID: 7113839606 Enrollment ID: O20031201000111 |
News Archive
Scientists at the University of Bonn and the Hebrew University of Jerusalem (Israel) have decoded a central signal cascade associated with epileptic seizures. If the researchers blocked a central switch in epileptic mice, the frequency and severity of the seizures decreased. Using a novel technology, it was possible to observe the processes prior to the occurrence of epileptic seizures in living animals.
Screening African Americans for microalbuminuria at either 5- or 10-year intervals would be highly cost-effective using a modified version of the CKD Health Policy Model, US researchers report.
Despite maturity in some segments, the European patient monitoring market still offers pockets of high growth potential. Unique strategies and technologically innovative products will sustain further expansion, even as the enthusiasm of patients and doctors for more sophisticated offerings will counteract challenges faced by the market.
The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.
Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lauren Elizabeth Kleess, MD Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | Ms Lauren Elizabeth Kleess, MD 1045 N 30th St, Billings, MT 59101-0738 Ph: (406) 238-2500 |
News Archive
Scientists at the University of Bonn and the Hebrew University of Jerusalem (Israel) have decoded a central signal cascade associated with epileptic seizures. If the researchers blocked a central switch in epileptic mice, the frequency and severity of the seizures decreased. Using a novel technology, it was possible to observe the processes prior to the occurrence of epileptic seizures in living animals.
Screening African Americans for microalbuminuria at either 5- or 10-year intervals would be highly cost-effective using a modified version of the CKD Health Policy Model, US researchers report.
Despite maturity in some segments, the European patient monitoring market still offers pockets of high growth potential. Unique strategies and technologically innovative products will sustain further expansion, even as the enthusiasm of patients and doctors for more sophisticated offerings will counteract challenges faced by the market.
The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.
Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.
› Verified 9 days ago
Charles Wittnam, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2675 Central Ave, Billings, MT 59102 Phone: 406-238-2500 | |
Phillip Embury Griffin, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2938 Rockrim Ln, Billings, MT 59102 Phone: 406-259-7582 | |
Megan B Littlefield, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Charles Mcclave, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N, Suite 160w, Billings, MT 59101 Phone: 406-237-8500 Fax: 406-237-8501 | |
Karen C. Klee, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Brock P. Whittenberger, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Benjamin Girton Plank, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |